I have 2 questions relating to Acadia that I would like to pose:
Assuming NNZ2591 is successful in one or more of its indications and the FDA approves availability in the US, what happens if it is used off-label for Rett or Fragile X. Who benefits (Acadia or Neuren) and would it be possible.
My second relates to the rights that Acadia holds for NNZ2591 for Rett and Fragile X - Under the agreement could Acadia sell those rights to a 3rd Party? Alternatively, if they choose not to progress with trials is there a time limit before they forfeit their rights. This may be more relevant to Fragile X
I would appreciate if anyone has thoughts on these questions. Apologies if these questions have been raised before but I am a casual visitor to Hotcopper
Thanks
Mangroves
NEU Price at posting:
$12.59 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)